Bioengineer.org: Biomarker may aid in determining treatment for cancer patients
UC medical student leads research to aid treatment of glioblastoma
Patients with glioblastomas or malignant brain tumors, face a difficult future. The disease is fatal, and only about 5 percent of patients are alive five years after their diagnosis, explains Haidn Foster, a third-year medical student at the UC College of Medicine and first author of a recent study of glioblastoma patients in the scholarly journal Neuro-Oncology Advances.
The findings were reported by Bioengineer.org, a biotechnology news service.
Foster’s study looked at health outcomes of 188 glioblastoma patients and found that individuals who tested positive for an antibody indicating Human cytomegalovirus (HCMV) exposure lived an average of 404 days after their cancer diagnosis compared to an average of 530 days for patients who were never infected by HCMV.
A life expectancy difference of four months is an important consideration for patients and their physicians. “For glioblastoma patients time is precious and treatment that would prolong life by a few weeks or months is considered a victory,” said Foster.
Related Stories
2024 Daniel Drake Medals to be awarded April 27
April 24, 2024
The UC College of Medicine will award three people with 2024 Daniel Drake Medals April 27.
Local 12: Head injury survivor, doctor share importance of...
April 23, 2024
Local 12 spoke with patient Shane Shapiro and the University of Cincinnati's Laura Ngwenya about the importance of wearing a helmet following Shapiro's traumatic brain injury and recovery.
UC hires Dr. Gregory Postel as senior vice president of health...
April 23, 2024
UC Board of Trustees vote to hire Dr. Gregory Postel as senior vice president of health affairs and dean of UC College of Medicine.